**Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990–2010**

Elizabeth Castañeda¹*, Clara Inés Agudelo¹, Rodrigo De Antonio², Diego Rosselli³, Claudia Calderón⁴, Eduardo Ortega-Barria⁵ and Rómulo E Colindres⁶

**Abstract**

**Background:** Pneumococcal conjugate vaccines (PCVs) are in the process of implementation in Latin America. Experience in developed countries has shown that they reduce the incidence of invasive and non-invasive disease. However, there is evidence that the introduction of PCVs in universal mass vaccination programs, combined with inappropriate and extensive use of antibiotics, could be associated to changes in non-PCV serotypes, including serotype 19A. We conducted a systematic review to determine the distribution of serotype 19A, burden of pneumococcal disease and antibiotic resistance in the region.

**Methods:** We performed a systematic review of serotype 19A data from observational and randomized clinical studies in the region, conducted between 1990 and 2010, for children under 6 years. Pooled prevalence estimates from surveillance activities with confidence intervals were calculated.

**Results:** We included 100 studies in 22 countries and extracted data from 63. These data reported 19,733 serotyped invasive pneumococcal isolates, 3.8% of which were serotype 19A. Serotype 19A isolates were responsible for 2.4% acute otitis media episodes, and accounted for 4.1% and 4.4% of 4,380 nasopharyngeal isolates from healthy children and in hospital-based/sick children, respectively. This serotype was stable over the twenty years of surveillance in the region. A total of 53.7% Spn19A isolates from meningitis cases and only 14% from non meningitis were resistant to penicillin.

**Conclusions:** Before widespread PCV implementation in this region, serotype 19A was responsible for a relatively small number of pneumococcal disease cases. With increased use of PCVs and a greater number of serotypes included, monitoring *S. pneumoniae* serotype distribution will be essential for understanding the epidemiology of pneumococcal disease.

**Keywords:** *Streptococcus pneumoniae* serotype 19A, Latin American and the Caribbean, Resistance to penicillin, Conjugate vaccines, Serotype replacement

**Background**

*Streptococcus pneumoniae* causes invasive pneumococcal disease (IPD), which is often life-threatening in children less than 2 years old, adults older than 65 years old and immunocompromised individuals [1]. Pneumococcus is also the most common cause of bacterial acute otitis media (AOM) and sinusitis in children [1-3].

The most important virulence factor in pneumococcus is the polysaccharide capsule, which forms the basis for serotyping and vaccine formulation; 93 distinct serotypes have been identified (with the recent inclusion of serotypes 6C, 6D and 11E) [3-6]. Worldwide, 20 serotypes account for more than 80% of IPD, although their prevalence varies by region [4]. A small number of pneumococcal resistant clones, serotypes 14, 23F, 6B, 6A, 9V, 15A, 19F and 19A, have spread and display particularly high rates of penicillin non susceptibility (PNSP) as well as multiresistance profiles (MDR) [7].
Since the introduction of pneumococcal conjugate vaccines (PCVs), numerous studies have been published on their safety, immunogenicity and efficacy, in particular for the heptavalent vaccine (PCV7), introduced in the USA in 2000 [8,9]. Studies conducted after PCV7 introduction, have shown dramatic and sustained decreases in vaccine type (VT) IPD rates, carriage and herd effects [10-13]. These positive findings were followed by reports of IPD caused by non vaccine types (NVT) S. pneumoniae PNSP and MDR [14-18]. NVT have also been described as agents of non invasive disease [15] and nasopharyngeal carriage [12]. Data from both North America and Europe have shown S. pneumoniae serotype 19A (Spn19A) to be the most prevalent serotype, associated with increasing rates of MDR [19]. Consequently, attention has focused on Spn19A, its prevalence and the numerous factors leading to this increase, and how best to control its impact [20-22].

This review summarizes the available published and unpublished Latin American and Caribbean (LAC) data from 1990 through 2010 describing the prevalence and burden of Spn19A in children less than 6 years. For comparison, we also analyzed the data for the most prevalent serotypes in this region [23].

Methods

We searched for data collected between January 1990 and July 2010 following PRISMA guidelines. Using both refined search strategies and broad spectrum, low specificity, searches (i.e. "Streptococcus pneumoniae" OR "pneumococcus" anywhere in the text), we reviewed all references on S. pneumoniae that were geographically linked to LAC countries, with no language restrictions; the targeted age group was children 6 years-old or younger. We searched the following databases: Medline (PubMed), Embase, Latin American and Caribbean Health Sciences Information (LILACS), Scientific Electronic Library on Line (SciELO) and SCOPUS. Search terms used are shown in Additional file 1a. Abstracts of recent meetings on infectious diseases were also included. Serotype distribution data were extracted by five reviewers for IPD, non-IPD and nasopharyngeal carriage. In addition, data on Spn19A penicillin susceptibility, pneumococcal disease prevalence and/or incidence, mortality rate, and pneumococcal vaccine potential impact were collected when available. For calculation of impact using SIREVA data we assumed serotype 6A/6B protection for PCV7 and PCV10 [4].

In order to avoid duplicate data, numbers were only added from the databases of the SIREVA Project (only for invasive isolates) available via the PAHO website, [23]. Data included in the analysis: 2000–2005, 2006, 2007, 2008 and 2009, SIREVA corresponded to available information in the original sources published according to the methodology used for this systematic review.

We limited selection bias by reducing the heterogeneity of samples; most data were from the SIREVA network for invasive isolates with standardized laboratory surveillance techniques and expanded availability of protocols. For the inclusion and exclusion criteria used to select publications reporting non IPD studies, we reviewed international criteria and internationally defined and accepted sample collection and laboratory techniques. For the purposes of this systematic review, we adopted the definitions presented in Additional file 1b.

We analyzed and presented our results following standard guidelines. Prevalence estimates were computed using the number of Spn19A isolates as the numerator and the total number of S. pneumoniae reported as denominator, for each study. Two techniques were used to calculate the pooled prevalence estimates: Mantel-Haenszel (fixed-effects model) and DerSimonian-Laird (random-effects model) [24,25].

For invasive disease meta-analysis we only included publications reporting non- SIREVA data, considering that SIREVA data represent 96.7% of samples analyzed and would bias the pool estimation.

Lastly, we estimated Spn19A specific IPD incidence by multiplying the serotype distribution by the reported incidences identified in this review.

Results

Study selection

Our searches retrieved a total of 1704 references. After reviewing the titles and abstracts, a total of 322 full texts were reviewed, 222 of which were excluded. The final number of publications included was 100 and data were extracted from 63; the remaining 37 were referenced (Figure 1). The characteristics of the 63 studies reviewed and of those that were referenced are described in Additional file 2.

The 63 references were divided into three categories: studies with information on invasive serotypes (n = 14), non-invasive isolates with individual information (n = 27) and burden of disease or disease incidence studies (n = 26). Four references provided information on more than one of these categories.

Spn19A in IPD

Most of the IPD isolates identified came from the SIREVA project (19084 of 19733; 96.7%) [23,26]. Of these 19733 isolates, 753 (3.8%) were Spn19A. There was no statistically significant difference in the prevalence of Spn19A isolates between SIREVA (3.8%) and non-SIREVA (3.1%) data (p = 0.3) (Tables 1 and 2).

When considering countries with more than 500 isolates collected over a period of 17 years (1993–2009) or 10 years (2000–2009) the total number of invasive isolates was 17831; 677 (3.9%) of these were Spn19A, ranging from 1.5% in Colombia to 7.0% in Venezuela (Table 1).
Analysis of the prevalence of invasive serotypes data from SIREVA (1993–2009) and non-SIREVA data (1989–2008) revealed that Spn19A ranked 9th in both sets of data (3.8% SIREVA and 3.1% non-SIREVA). In an analysis of the SIREVA data in 20 countries, Spn19A ranked 9th (3.6%) for the period 2000–2005, and 8th (4.6%) for the period 2006–2009.

The prevalence of Spn19A in the region, by country and by time period is shown in Table 3. Spn19A accounted for 3.3% (CI95%: 1.8–4.9) of isolates between 1993 and 1999, 3.6% (CI95%: 2.3–4.9) between 2000 and 2005, and 4.6% (CI95%: 3.4–5.8) between 2006 and 2009 (p < 0.001). The prevalence of serotypes recorded from SIREVA data collected during the three time periods presented by vaccine type (VT) (PCV7, PCV10, PCV13) and non vaccine type (NVT), as well as Spn19A, prevalence by region (SIREVA) (Average cases by study period (2000–2005 vs. 2006–2009) is shown in Additional file 4. Analysis by SIREVA reports are presented in Figure 2.

We did not observe any statistical significant differences in the prevalence of Spn19A isolates reported between age groups (4.9% for <2 years vs. 5% for 2–5 years; p = 0.8), for the period 2007–2009 (See Additional file 5).

Spn19A was reported less frequently in meningitis cases (3.0%) than in non-meningitis (4.6%; p < 0.01), with the exception of Paraguay (2.8% vs. 2.0%). Differences were statistically significant only for Brazil (3.0% vs. 4.8%; p = 0.009) (See Additional file 6a).

SIREVA data from the period 2006–2007 [23] showed that pneumonia accounted for 59.4% of non-meningitis cases (1069/1801) and 56% of all Spn19A (42/75). Overall, Spn19A accounted for 3.9% of the pneumonia isolates in LAC (See Additional file 6b). Data from 2000–2009, showed that Spn19A was the 10th and 6th most frequently reported serotype causing meningitis and non-meningitis, respectively (See Additional files 6c and d).

In non-SIREVA data from studies in Argentina [27] and Brazil [29], Spn19A accounted for 1.3% (2/152) of meningitis and none of the 146 non-meningitis.

Spn19A in AOM

Data showing the frequency of serotype 19A amongst isolates in cases of acute otitis media are presented in Table 4. Despite representing more than 70% of the whole sample,
only 0.6% of Costa Rican isolates were Spn19A. Data grouped by VT (13, 10 and 7 valent vaccines) and NVT are also shown (See Additional file 7a). Overall, Spn19A accounted for 2.4% (11/460) of isolates, ranking the 9th amongst the most frequent serotype for AOM.

Table 1 Streptococcus pneumoniae serotype 19A, number of invasive isolates by country, SIREVA data, 1993-2009

| Country | Year of isolation | Serotype 19A | Total |
|---------|------------------|-------------|-------|
|         |                  | n | %    | n     |
| Argentina | 1993–2009        | 100 | 3.7 | 2692 |
| Bolivia  | 2000–2009        | 5  | 3.1 | 160  |
| Brazil   | 1993–2009        | 153 | 3.6 | 4262 |
| CARECa   | 2000–2009        | 2  | 1.4 | 148  |
| Chile    | 1993–2009        | 161 | 4.5 | 3617 |
| Colombia | 1993–2009        | 28  | 1.5 | 1819 |
| Costa Rica | 2000–2009      | 3  | 4.8 | 63   |
| Cuba     | 2000–2009        | 31  | 3.4 | 899  |
| DRb      | 2000–2009        | 14  | 2.6 | 544  |
| Ecuador  | 2000–2009        | 5  | 2.3 | 215  |
| El Salvador | 2000–2009    | 5  | 9.6 | 52   |
| Guatemala | 2000–2009       | 11  | 9.3 | 118  |
| Honduras | 2000–2009        | 0  | 0.0 | 11   |
| Mexico   | 1993–2009        | 91  | 6.2 | 1463 |
| Nicaragua | 2000–2009       | 2  | 4.7 | 43   |
| Panama   | 2000–2009        | 15  | 7.7 | 194  |
| Paraguay | 2000–2009        | 17  | 2.2 | 784  |
| Peru     | 2000–2009        | 8  | 3.2 | 249  |
| Uruguay  | 1993–2009        | 44  | 3.6 | 1210 |
| Venezuela | 2000–2009       | 38  | 7.0 | 541  |
| Total    |                  | 733 | 3.8 | 19084|

Table 2 Streptococcus pneumoniae serotype 19A, number of invasive isolates by country, non SIREVA data, 1989–2008

| Country [Reference] | Year of isolation | Serotype 19A | Total |
|---------------------|------------------|-------------|-------|
|                     |                  | n | % | n |
| Argentinaa [27]b | 1999–2002        | 0 | 0.0 | 153 |
| Brazilc [28] | 1989–1993        | 2 | 4.1 | 49  |
| Brazila [29] | 1995–1999        | 2 | 1.4 | 145 |
| Chile [30]b | 1994–2004        | 3 | 2.3 | 128 |
| Chile [31]b | 1995–1997        | 1 | 3.3 | 30  |
| Mexicob [32] | 1992–1993        | 11 | 9.2 | 120 |
| Colombia [33]b | 2008             | 1 | 4.2 | 20  |
| Total              |                  | 20 | 3.1 | 649 |

a Meningitis.
b Unspecified invasive disease.
c Caribbean Epidemiology Centre.

Only 0.6% of Costa Rican isolates were Spn19A. Data grouped by VT (13, 10 and 7 valent vaccines) and NVT are also shown (See Additional file 7a). Overall, Spn19A accounted for 2.4% (11/460) of isolates, ranking the 9th amongst the most frequent serotype for AOM.

Table 3 Streptococcus pneumoniae serotype 19A prevalence in 20 countries, SIREVA data, 1993–2009

| Country | Periods analyzed [Reference] | Serotype 19A | Total |
|---------|-----------------------------|-------------|-------|
|         | 1993–1999 [26] | 19A | Total | 19A | Total | 19A | Total |
|         | n | % | n | n | n |
| Argentinaa | 30 | 3.0 | 1006 | 33 | 3.5 | 936 | 37 | 4.9 | 750 |
| Boliviab | - | - | - | 3 | 2.8 | 108 | 2 | 3.8 | 52 |
| Brazil | 42 | 3.5 | 1203 | 71 | 3.6 | 1963 | 40 | 3.6 | 1096 |
| CAREC | - | - | - | 1 | 0.9 | 110 | 1 | 2.6 | 38 |
| Chile | 19 | 4.1 | 461 | 81 | 4.3 | 1894 | 61 | 4.8 | 1262 |
| Colombiaa | 4 | 0.6 | 623 | 6 | 0.9 | 647 | 18 | 3.3 | 549 |
| Costa Rica | - | - | - | 0 | 0.0 | 3 | 3 | 5.0 | 60 |
| Cuba | - | - | - | 28 | 3.3 | 842 | 3 | 5.3 | 57 |
| DR | - | - | - | 8 | 2.1 | 379 | 6 | 3.6 | 165 |
| Ecuador | - | - | - | 0 | 0.0 | 55 | 5 | 3.1 | 160 |
| El Salvador | - | - | - | 3 | 13.0 | 23 | 2 | 6.9 | 29 |
| Guatemala | - | - | - | 4 | 4.4 | 91 | 7 | 25.9 | 27 |
| Honduras | - | - | - | 0 | 0.0 | 3 | 0 | 0.0 | 8 |
| Mexico | 28 | 6.6 | 426 | 42 | 5.8 | 728 | 21 | 6.8 | 309 |
| Nicaragua | - | - | - | 1 | 2.6 | 39 | 1 | 25.0 | 4 |
| Panamba | - | - | - | 7 | 6.9 | 101 | 8 | 8.6 | 93 |
| Paraguay | - | - | - | 12 | 2.5 | 477 | 5 | 1.6 | 307 |
| Peru | - | - | - | 3 | 2.1 | 143 | 5 | 4.7 | 106 |
| Uruguay | 13 | 3.7 | 352 | 18 | 3.1 | 575 | 13 | 4.6 | 283 |
| Venezuela | - | - | - | 24 | 5.9 | 407 | 14 | 10.4 | 134 |
| Total | 136 | 3.3 | 4071 | 345 | 3.6 | 9524 | 252 | 4.6 | 5489 |

a Significant differences between 1993–1999 and 2006–2009 (Argentina p = 0.03, Colombia p < 0.001).
b Caribbean Epidemiology Centre.
c Dominican Republic.
- No data available.

Prevalence in 20 countries. SIREVA data, 1993–2009.

Spn19A in nasopharyngeal carriage

Spn19A data from isolates in healthy children are shown in Table 4; 20 serotypes were identified for 74.7% of nasopharyngeal isolates, of which serotype 19F was the most frequently reported (13.6 and Spn19A the 6th (4.1%) (See Additional file 7b).

The distribution of Spn19A in healthy children (carriage) was similar from that seen for the smaller sample of isolates collected from sick children (Table 4), where Spn19A was the 5th most frequently reported serotype (4.4% of total isolates) (See Additional file 7c).

S. pneumoniae susceptibility to penicillin. Serotype 19A and other serotypes (2007–2009)

A total of 53.7% (22/41) of Spn19A isolates collected from meningitis cases were reported to be resistant. For non-meningitis isolates 10.8% of Spn19A isolates (17/
158) showed an intermediate level of resistance and 3.2% (5/158), high resistance (Table 5) [61].

An analysis of other serotypes showed that among 453 resistant meningeal isolates, Spn19A was the 5th most frequently reported serotype (4.9%) and that, for 248 resistant non-meningitis isolates, it was 3rd (8.3%) (See Additional file 8a). These data are presented by country in Additional file 8b.

**Spn19A meta-analysis**

For invasive disease, our analysis of the data shows 1% prevalence overall for this serotype, ranging from 0.03% in Argentina to 9.2% in Mexico [27-33] (Figure 3a).

The prevalence of Spn19A in AOM was 0.8%, ranging from 0.6% in Costa Rica to 16.7% in Mexico [35-37,39] (Figure 3b).

The overall prevalence of Spn19A in healthy carriers, for 9 different countries, was 2.5%, ranging from 0.4% for studies conducted in Mexico between 2002 and 2003 period to 10.8% for studies conducted in Mexico in 2006, respectively [38-56] (Figure 3c). For sick children, the overall prevalence for 4 countries was 2.7%, ranging from 1.6% in Venezuela to 11.1% in Brazil [48,54,57-60] (Figure 3d).

**Spn19A burden of disease**

Our literature search for publications on the burden of disease caused by serotype 19A identified 26 papers; Table 6 summarizes incidence rates reported. Incidences by country are presented in Additional file 9.

Lagos et al. [46] monitored IPD related hospitalizations in Chile between 1994 and 2007. Among the serotypes identified, “other” or “non-vaccine serotypes within vaccine serogroups” (which included Spn19A) were reported for 72 patients with invasive clinical syndromes. For these patients, the case fatality rate was 0%. The annual incidence of IPD among children 0–59 months of age caused by Spn19A was 1 per 100,000.

In Córdoba, Argentina, Tregnaghi et al. [27] found a highest incidence of IPD (206/100,000 children <2 years old), attributed to ambulatory patients. No Spn19A isolates were isolated.
The scope of our search strategy allowed us to retrieve comprehensive lists of peer-reviewed publications. Two of our authors being members of the SIREVA team, we were able to identify the vast majority of relevant publications in non-indexed journals and obtain personal communications with SIREVA coordinators [23]. Additionally, information retrieved from over a 20 year period evaluated secular trends and the periodicity of serotypes described in the literature [1-4].

A strength of our analysis is that the percentage of IPD Spn19A isolates reported in the non SIREVA data that we reviewed (7 reports, 1990–2008) was not significantly different from that for the SIREVA data (3.8%).

Regarding time period of Spn19A prevalence, a significant increase, from 3.3% to 4.6%, was noted only in Argentina and Colombia between 1994–1999 and 2006–2009 before any universal vaccine intervention could have had an impact. However, Spn19A stability was observed in Brazil, Chile, Dominican Republic and Mexico. Similar increases in the percentage of isolates accounted for Spn19A, even prior to the introduction of PCV7, have been reported in Europe [63], South Korea [64], Southern Israel [65] and Taiwan [66], likely reflecting selection pressure from antibiotic use.

On the other hand, in the USA the observed increasing prevalence of PRSP and MDR Spn19A has been suggested to be due to a rapid expansion of the Spn19A clonal complex CC320, to more than one new clone introduced or to successful clones associated with other serotypes that have undergone a recombinational switch to Spn19A [20,21].

In the LAC region only one study, describing PFGE patterns of Spn19A isolates, and conducted in Colombia [67], reported Spn19A MDR isolates in IPD; two were found related to the clone Colombia23F-ST338, one to the clone Spain23F-ST81, and 6 were not related to the clones studied. A possible explanation of these findings may be that a successful clone, such as Spain23F, underwent a recombinational switch to Spn19A.

No differences could be established between age groups for the prevalence of Spn19A as an IPD agent. In contrast, serotypes 1 and 5 were more frequent in children 2–5 years old and serotypes 6B and 14 were more frequent in <2 year olds than in the other age groups in the LAC region (See Additional file 5).

Our analysis suggests that Spn19A causing IPD in LAC is more frequently an agent of non-meningitis disease (4.5% of cases), in particular pneumonia than of meningitis (2.9%) (See Additional file 6a).

PNSP in invasive Spn19A isolates has been reported in LAC since 1993 [26]. A study conducted in 2010, using the new CLSI breakpoints for penicillin [61], showed that resistant Spn19A isolates are circulating in the region, more frequently as agents of meningitis (MIC ≥0.125 μg/ml) than for of non-meningitis (MIC ≥4.0 μg/ml). However,
the finding of a prevalence of 3.2% for Spn19A with MIC $\geq$ 8.0 μg/ml among non-meningitis cases, recovered in Mexico, Colombia and Venezuela is of great concern, as it follows reports of 7.7% of cases being attributed to serotype 19F. Molecular surveillance data will reveal their role as agents of pneumococcal disease [20,21].

Despite the fact that S. pneumoniae causes 30–60% of AOM cases worldwide [68], only three papers and one abstract were found and analyzed; overall, 2.4% of these were attributed to Spn19A. As AOM continues to be an important childhood infection and that the etiology might change from VT to non-PCV7 strains once pneumococcal vaccines are widely implemented [69], it is important to conduct AOM etiology studies in the region. S. pneumoniae may be subject to serotype replacement phenomena and attention to antibiotic resistant NVT otopathogens as well as non typable Haemophilus influenzae is required [70].

Nasopharyngeal carriage has been confirmed with greater values reported for children less than 5 years old. From the papers analyzed, Spn19A ranked the 6th most frequently reported serotype for healthy children (4.1%), jointly with Non-Typable. There were a high number of serotypes with ability for colonizing the nasopharynx, with serotype 19F the most frequently identified (See Additional file 7b). Nasopharyngeal serotypes described in Latin America from 1994 to 2008 are very similar to those described by

Figure 3 a Serotype 19A meta-analysis of invasive isolates. b Serotype 19A meta-analysis of AOM isolates. c Serotype 19A meta-analysis healthy nasopharyngeal carriers. d Serotype 19A meta-analysis sick carriers.
Huang in 2001 (pre vaccine data) for generally healthy children in 16 Massachusetts communities. Spn19A represented 4.2% of 143 isolates; PNSP was described for 77% of the isolates. Studies conducted since the introduction of PCV7 vaccine have shown decreases in colonization with pneumococcal VT shortly after immunization as well as longer-term changes in colonization patterns. Huang [12] reported a decrease in the carriage of VT from 36% to 3% seven years after mass introduction of PCV7, whereas NVT carriage increased from 15% to 29%. The common colonizing serotypes in 2007 included 19A (16%) (Baseline data 6.0%), 6A (12%), 15B/C (11%), 35B (9%) and 11A (8%), a clear reflection of the replacement phenomenon. Additionally, the more frequent colonizing serotypes have greater resistance to penicillin. Nasopharyngeal surveillance appears to be a reliable system for measuring vaccination impact in terms of a decrease in VT types and will help to elucidate the emergence of NVT following PCV introduction.

Incidence rates reported by Lagos [46] for IPD caused by Spn19A ranged from 0.4 to 2.2 cases x 100,000 between 1994 and 2007, suggesting a seasonal pattern for this serotype. Similar variations have been shown for other serotypes in the LAC region, such as 1 and 5 [34] and may explain changes during time periods in the SIREVA data presented in this review. This should be considered when interpreting data post introduction of pneumococcal vaccines in this region. In contrast, the incidence of other serotypes such as 14 has shown small variations [26,34].

PCVs have been introduced recently in several countries in LAC, but currently, there are no data published about their impact in reducing IPD. Consequently, little is known about the replacement phenomenon with Spn19A, which has been well described previously [22]. Available data provide only an estimation of hypothetical impact (supplement 10). The same calculation for the recent SIREVA data [4] showed a major impact of PCV10 and PCV13 vaccination, in particular related to the inclusion of serotypes 1 and 5. In fact, after 2009, countries in the region have incorporated different PCV into their expanded program of immunization following individual assessment for their epidemiology (PCV7/13: Costa Rica, Uruguay, Mexico and PCV-10: Brazil, Colombia, Ecuador and Chile). Following the results of this review, indicating the low prevalence of Spn19A in most of the countries, it is necessary to report any subsequent change in the distribution of this serotype in those countries who have introduced one of the available PCVs. Particularly, trying to explain any increase or decrease in the Spn19A prevalence comparing the statistics prior to universal vaccination and possible factors that could explain this, such as vaccine coverage, antibiotic use and immune response based on the vaccine formulation.

The results of our systematic review have a number of limitations. The source of primary data, either from SIREVA or from independent research teams, could introduce selection bias, potentially promoting the selection of more severe forms of the disease. However, it is important to highlight that more severe disease will have the largest impact from a burden of disease or a public health perspective. Information on disease severity caused by Spn19A in this region was limited; this is also the case for data collected for other serotypes, given that similar surveillance activities are employed in the different countries. As this limitation is not restricted to a specific serotype, it should not bias our conclusions. It was not possible to analyze temporal changes in serotype frequency, except from a very broad perspective. The small amount of data available on burden of disease and on the possible effects of mass vaccination highlights the need for more research in this area.

Incidence of IPD in this region ranges from 3.0 to 206.8 cases per 100,000. Overall 9 serotypes are responsible for 80% of IPD and 30% are due to serotype 14; Spn19A remains relatively uncommon as an agent of

### Table 6 Estimates of the incidence rate of different pneumococcal diseases in Latin America and the Caribbean and S. pneumoniae 19A specific incidence

| Condition                        | Range expressed in cases per 100,000/year | Age group (years) |
|----------------------------------|------------------------------------------|-------------------|
| Invasive pneumococcal disease IPD| 61 (58–63)*                              | <1                |
| S. pneumoniae 19A specific incidence** | 2.3 (2.2–2.9)                              | <2                |
| Pneumococcal meningitis          | 19                                        | <3                |
| S. pneumoniae 19A specific incidence^ | 0.6 (0.4–0.7)                              | <5                |
| Pneumococcal pneumonia           | 51 (47–55)                                |                  |
| S. pneumoniae 19A specific incidenceµ | 1.98 (1.8–2.1)                             |                  |
| Pneumococcal sepsis              | 12                                        |                  |
| S. pneumoniae 19A specific incidence£ | 0.6                                       |                  |
| Pneumococcal bacteremia          | 2                                         |                  |
| S. pneumoniae 19A specific incidence¤ | 0.2                                       |                  |

(Adapted from reference [62]).

* (25th–75th percentile, when reported).
** S. pneumoniae 19A distribution reported in SIREVA 1993–2009 = 3.8%.
µ S. pneumoniae 19A distribution reported in SIREVA 2000–2009 = 3.0%.
£ S. pneumoniae 19A distribution reported in SIREVA 2006–2007 = 3.9%.
¤ S. pneumoniae 19A distribution reported in SIREVA 2000–2009 = 4.6%.
IPD, with the exception of Mexico and Venezuela. Data on non invasive disease and nasopharyngeal carriage, although not as robust, show the same low prevalence.

Conclusions
As several countries in the region implemented PCV in their routine schedules starting in 2006, regional data on vaccination impact on IPD, non invasive and nasopharyngeal carriage by VT and herd effect should soon be available. In the near future we expect that data on VT and NVT, supported by a solid surveillance system, will be available, which will support public health decisions on the introduction of PCV.

Additional files

Additional file 1: a- *Streptococcus pneumoniae* serotype 19A, search strategies. b- *Streptococcus pneumoniae* definitions.

Additional file 2: Characteristics of the 63 studies included in the analysis, SIREVA and non SIREVA [2,27-60,62,71-135].

Additional file 3: Characteristics of the 63 studies included in the analysis, SIREVA and non SIREVA [2,27-60,62,71-135].

Additional file 4: *Streptococcus pneumoniae*, serotype prevalence in three time periods of SIREVA results presented by vaccine type (VT) (PCV7, PCV10, PCV13) and non vaccine type (NVT). [75,82,86,89,97].

Additional file 5: *Streptococcus pneumoniae*. Serotype distribution for invasive isolates by age group <2 years and 2–5 years. SIREVA data, 2007–2009 [86,89,97].

Additional file 6: a- *Streptococcus pneumoniae* serotype 19A. Meningitis, non-meningitis in ten countries. SIREVA data, 2000–2009. b- *Streptococcus pneumoniae* serotype 19A. Non-meningitis and pneumococcal cases in 20 countries. SIREVA data, 2000–2007. c- *Streptococcus pneumoniae* Meningitis isolates by country and serotype presented by vaccine type (VT) (PCV7, PCV10, PCV13) and non vaccine type (NVT). SIREVA data, 2000–2009. d- *Streptococcus pneumoniae*. Non-meningitis isolates by country and serotype presented by vaccine type (VT) (PCV7, PCV10, PCV13) and non vaccine type (NVT). SIREVA data, 2000–2009 [348,82,85,86,89,97].

Additional file 7: a- *Streptococcus pneumoniae*. Number of acute otitis media isolates presented by vaccine type (VT) (PCV7, PCV10, PCV13) and non vaccine type (NVT). b- *Streptococcus pneumoniae*. Number of nasopharyngeal isolates in healthy children presented by vaccine type (VT) (PCV7, PCV10, PCV13) and non vaccine type (NVT). c- *Streptococcus pneumoniae*. Number of nasopharyngeal isolates in sick children presented by vaccine type (VT) (PCV7, PCV10, PCV13) and non vaccine type (NVT). SIREVA data, 2000–2009 [348,82,85,86,89,97].

Additional file 8: a- *Streptococcus pneumoniae*. Meningitis and non-meningitis isolates, penicillin resistance by serotype. SIREVA data 2007–2009. b- *Streptococcus pneumoniae* serotype 19A. Meningitis isolates, penicillin resistance. Argentina, Brazil, Colombia, Mexico and Venezuela. 2007–2009 [86,89,97].

Additional file 9: Pneumococcal diseases in Latin America and the Caribbean incidences by country [27,29,33,46,77-79,83,134,135].

Additional file 10: Pneumococcal vaccines. Hypothetical vaccine impact, population <6 years [27-30,32-36,40-42,46,49,50,55,56,58,74,75,82,85-90,97,108,112,113,117,119,123,129]

Additional file 11: *Streptococcus pneumoniae* serotype 19A prevalence in the region. SIREVA data 2000–2009.

Competing interests
Elizabeth Castañeda, Clara Inés Agudelo, Diego Rosselli and Claudia Calderón no conflicts to declare.
Rodrigo De Antonio, Eduardo Ortega-Barria and Romulo E Colindres are employees of GlaxoSmithKline Biologicals. Eduardo Ortega-Barria and Romulo E Colindres have stock ownership; Rodrigo De Antonio has stock options.

Authors’ contributions
EC contributed to systematic review conception and design, data analysis, interpretation of data, elaboration, review and comments on all drafts of this paper and gave final approval to submit for publication. CIA contributed to systematic review conception and design, data analysis, interpretation of data, elaboration, review and comments on all drafts of this paper and gave final approval to submit for publication. RDA contributed to systematic review conception and design, data analysis, interpretation of data, review and comments on all drafts of this paper and gave final approval to submit for publication. DR contributed to systematic review conception and design, data analysis, interpretation of data, review and comments on all drafts of this paper and gave final approval to submit for publication. CC contributed to systematic review conception and design, data analysis, interpretation of data, review and comments on all drafts of this paper and gave final approval to submit for publication. REC contributed to systematic review conception and design, interpretation of data, review and comments on all drafts of this paper and gave final approval to submit for publication. All authors read and approved the final manuscript.

Acknowledgements
Authors would like to thank Juliette Gray (XPE Pharma & Science, on behalf of GlaxoSmithKline) for her valuable contribution in editorial support. GlaxoSmithKline Biologicals funded the study.

Author details
1Instituto Nacional de Salud Bogotá, Bogotá, Colombia. 2GlaxoSmithKline Biologicals, Panama City, Panama. 3Department of Clinical Epidemiology and Biostatistics, Universidad Javeriana Medical School, Bogotá, Colombia. 4Independent investigator, Bogotá, Colombia. 5GlaxoSmithKline Biologicals, Rio de Janeiro, Brazil. 6GlaxoSmithKline Biologicals, Wavre, Belgium.

Received: 3 October 2011 Accepted: 27 March 2012 Published: 28 May 2012

References
1. Lynch JP 3rd, Zhanel G: *Streptococcus pneumoniae*: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. *Curr Opin Pulm Med* 2010, 16:217–225.
2. O’Brien KL, Wolton LJ, Watt JP, Henkle E, Deloria-Knoll M, McCaull N, Lee E, Mulholland K, Levine OS, Chenier T, Hib and Pneumococcal Global Burden of Disease Team: Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. *Lancet* 2009, 374:893–902.
3. Levine OS, Knoll MD, Jones A, Walker DG, Risco N, Glazi Z: Global status of *Haemophilus influenzae* type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. *Curr Opin Infect Dis* 2010, 23:236–241.
4. Johnson HL, Deloria-Knoll M, Levine OS, Stovzek SK, Freimanis Hance L, Reithinger R, Muren UR, O’Brien KL: Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. *PLoS Med* 2010, 7:e1000348. doi:10.1371/journal.pmed.1000348.
5. Satzke C, Ortilko BD, Ofahed S, Russell FM, Robins-Browne RM, Mulholland EK, Gilbert GJ: Molecular epidemiology of *Streptococcus pneumoniae* serogroup 6 isolates from Fijiian children, including newly identified serotypes 6C and 6D. *J Clin Microbiol* 2010, 48:4298–4300.
6. Calix JJ, Nahm MH: A new pneumococcal serotype, 11E, has a variably inactivated wce gene. *J Infect Dis* 2010, 202:29–39.
7. Pneumococcal Molecular Epidemiology Network (PMEN). Clone Collection. [http://www.sph.emory.edu/PMEN/PMEN_clone_collection.html](http://www.sph.emory.edu/PMEN/PMEN_clone_collection.html)
23. Pan American Health Organization. PAHO: SIREVA II

5. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. Active bacterial core surveillance of the emerging infections program network. Decline in invasive pneumococcal disease after introduction of protein-polysaccharide conjugate vaccine. New Engl J Med 2003; 348:1737–1746.

9. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Jorgensen JH, Lexau CA, Petti S, Reingold A, Schaffner W, Thomas A, Whitney CG, Harrison LH. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2006, 354:1455–1463. Erratum in: N Engl J Med 2006.

10. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, Farley MM, Jorgensen JH, Lexau CA, Petti S, Reingold A, Schaffner W, Thomas A, Whitney CG, Harrison LH. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360:244–256.

12. Huang SS, Hinrichsen VL, Stevenson AV, Pelton KL, Kuehnert MJ, Schuchat A, Jorgensen JH, Beall B, Mason EO Jr. Active bacterial core surveillance of the future emerging infections program network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32–41.

15. Pichichero ME, Casey JR. http://www.biomedcentral.com/1471-2334/12/124

18. Techasaensiri C, Messina AF, Katz K, Ahmad N, Huang R, McCracken GH Jr. Emergence of 19A as virulent and multidrug resistant pneumococci in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007, 26:468–472.

19. Kaplan SL, Barson WJ, Lin PL, Stovall SH, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO Jr. Serotype 19A is the most common serotype causing pneumococcal meningitis. J Infect Dis 2010, 201:770–775.

20. Inostroza J, Illesca V, Reynes M, Josset L, Jiménez-Rojas V. Ten-year surveillance of pneumococcal infections in Temuco, Chile: Implications for vaccination strategies. Clin Vaccine Immunol 2007, 14:560–564.

22. http://www.abstractserver.com/

25. Shrout P, Fleiss J: Intraclass correlations: uses in assessing rater reliability. Educ Psychol Meas 1979, 39:419-428.

26. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000, 283:232–235.

27. Talbot JA, De Quadros C, Echániz-Avilés G, Noemi M, Barajas C, Heitmann I, Hormazabal JC, Brandi-lone MC, Dias Vieira VS, Regueira M, Ruvinsky R, Corso A, Lowgren M, Talbot JA, De Quadros C. Evolution of Streptococcus pneumoniae serotypes and penicillin susceptibility in Latin America, Sireva-Viga Group, 1993 to 1999. Pediatr Infect Dis J 2001, 20:595–597.

28. Tregnaghi M, Ceballos A, Ruttimann R, Peeters P, Tregnaghi JP, Utzschner J, De Luca R, D’Hollander P, Rüedi RO. Vigilancia epidemiológica activa de la enfermedad neumocócica en lactantes, en el ámbito ambulatorio y en la internacional. Arch Argent Pediatr 2006, 104:3–11.

30. Inostroza J, Illesca V, Reynes M, Josset L, Jiménez-Rojas V. Ten-year surveillance of pneumococcal infections in Temuco, Chile: Implications for vaccination strategies. Clin Vaccine Immunol 2007, 14:560–564.

32. Naves MA, Lamy P, Regueira M, Corso A, Spn Working Group. Reduced incidence of pneumococcal disease caused by nonvaccine-serotype invasive pneumococci among non-vaccinated children in the SIREVA II surveillance. Clin Vaccine Immunol 2009, 16:1760–1764.

34. Schuchat A, Facklam RR, Reis MG, Ko AI: Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae from meningitis patients in Salvador, Brazil. J Clin Microbiol 2002, 40:275–277.

36. Vigilancia de los Agentes Responsables de Neumonías y Meningitis (Sistema de Redes de Vigilancia de los Agentes Responsables de Neumonías y Meningitis Bacterianas). [http://new.paho.org/hq/index.php?option=com_content&view=blogcategory&id=3609&Itemid=3953]
serotypes and the conjugated heptavalent pneumococcal vaccine. J Pediatr (Rio J) 2003; 79(2):152–200.
41. Laval CB, de Andrade AL, Pimenta FC, de Andrade JG, de Oliveira RM, Silva AL, de Lima EC, Fabio JL, Casagrande ST, Brandileone MC. Serotypes of carriage and invasive isolates of Streptococcus pneumoniae in Brazilian children in the era of pneumococcal vaccines. Clin Microbiol Infect 2006, 12:420–55.
42. Reis JN, Palma T, Ribeiro GS, Pinheiro RM, Ribeiro CT, Cordeiro SM, da Silva Filho HP, Moschioni M, Thompson TA, Spratt B, Riley LW, Barocchi MA, Reis MG, Ko AI: Transmission of Streptococcus pneumoniae in an urban slum community. J Infect Dis 2008, 57:204–213.
43. Franco CM, Andrade AL, Andrade JG, Almeida e Silva S, Oliveira CR, Pimenta FC, Lamaro-Cardoso J, Brandão AP, Almeida SC, Galv JJ, Nahm MH, de Cunto Brandileone MC. Survey of nonsusceptible nasopharyngeal Streptococcus pneumoniae isolates in children attending day-care centers in Brazil. Pediatr Infect Dis J 2010, 29:77–79.
44. Gherardi G, Inostroza JS, O´Ryan M, Prado V, Prieto S, Arellano C, Facklam RR, Solórzano-Santos F, Ortiz-Ocampo LA, Miranda-Novales MG, Echániz-Avilés M. High prevalence of serotype 11B of Streptococcus pneumoniae in children attending day-care centers in Brazil. Pediatr Infect Dis J 2010, 29:77–79.
45. Quintero B, Araque M: Perfil serológico y antibiotipia de cepas de Streptococcus pneumoniae aisladas de portadores nasales pediátricos. Invest Clin 2006, 47:17–26.
46. Azevedo J, Galvão VS, Sant’Anna V, da Matta TF, Cordeiro SM, MG Reis dos, Ko AI, Reis JN, Campos LC: Pneumococcal carriage profile in Brazilian pediatric patients from the pre-vaccine era. Presented at: 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-7). Tel-Aviv 2010. http://www.abstractserver.com/isppd2010/planner/sp.php?go=abstract&action=abstract_iplanner&absno=503&ISPPD2010=6f9ter81ucelvs98apjgo40pe1&ISPPD2010=6f9ter81ucelvs98apjgo40pe1.
47. Hortal M, Camou T, Palacio R, Dibarboure H, García A: Public health impact of colonization with Streptococcus pneumoniae serotype 19A. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases (WSPID). Tel-Aviv 2010. http://www.abstractserver.com/isppd2010/planner/sp.php?go=abstract&action=abstract_iplanner&absno=515&ISPPD2010=6f9ter81ucelvs98apjgo40pe1&ISPPD2010=6f9ter81ucelvs98apjgo40pe1.
48. Varon E, Verhaegen J: Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis 2010, 16:1428–1430.
49. Guey JD, Adlowitz DG, Pichichero ME: New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010, 29:304–309.
50. Collier TR, Chan LS, Newberry SJ, Limbos MA, Suttrop MJ, Shekelle PG, Takata GS: Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA 2010, 304:161–2169.
51. Lopez Bravo I, Sepulveda H, Valdes I: Acute respiratory illnesses in the first 18 months of life. Rev Panam Salud Publica 1997, 3:17–17.
52. Magnus SA, Hambleton IR, Moosdeen F, Serjeant GR: Emergence and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009, 199:768–785.
53. Hsieh YC, Lin PY, Chiu CH, Huang YC, Chang KY, Liao CH, Chiu NC, Chuang YC, Chen PY, Chang SC, Liu JW, Yen MY, Wang JH, Liu CY, Lin TY: National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 2009, 27:5513–5518.
54. Wildgoose M, Santors K, Barros C, Gasco C, Zappolo E, Aguado C: Incremento da resistência a eritromicina de Streptococcus pneumoniae. Rev Panam Salud Pública 1994–2003. Biomédica 2011, 31:124–131.
55. Rodgers GL, Arguedas A, Cohen R, Dagan R: Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 2009, 27:3820–3821.
56. Bello González T, Rivera-Olivero IA, Pocaterra L, Spadola E, Aracne M, Herrmans PW, de Waard JH: Pneumococcal carriage among indigenous Warao children in Venezuela: serotypes, susceptibility patterns, and molecular epidemiology. Clin Infect Dis 2007, 45:1427–1434.
57. Beanez EN, Cardenas MD, Feirera LL, Otsuka M, Guerra ML, Brandileone MC: Distribution of Streptococcus pneumoniae serotypes in nasopharyngeal carriage and in invasive pneumococcal disease in Sao Paulo, Brazil. Pediatr Infect Dis J 2007, 26:643–645.
58. Bello González T, Rivera-Olivero IA, Pocaterra L, Spadola E, Aracne M, Herrmans PW, de Waard JH: Pneumococcal carriage among indigenous Warao children in Venezuela: serotypes, susceptibility patterns, and molecular epidemiology. Clin Infect Dis 2007, 45:1427–1434.
admissions in children before and during the year of intervention. Uruguay. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases. Buenos Aires: WSPID; 2009 [http://www.abstractserver.com/wspid09/planner/sp.php?go=abstract&action=abstract_iplanner&absno=793]

93. Gligo N, Cane A, Ferreiro E: Evaluation of cost-effectiveness of three vaccination scenarios with pneumococcal conjugated vaccines. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases. Buenos Aires: WSPID; 2009 [http://www.abstractserver.com/wspid09/planner/sp.php?go=abstract&action=abstract_iplanner&absno=314]

94. González Ayala S, Vescina C, Agosti M, Morales J, Marone J, Requejua M, Moncioni L: Pneumococcal meningitis at an Argentinean municipality. Presented at: 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-7), Tel-Aviv, Israel, 2010 [http://www.abstractserver.com/sppd2010/planner/sp.php?go=abstract&action=abstract_iplanner&absno=520]

95. Gutierrez S, Boix A, Gotelo G, Silva L: Bacterial pneumonia. Hospital admission to the Sindicato Medico Uruguay (CASMU) one year before and after introduction of 7-valent pneumococcal vaccine. Presented at: 6th Annual Meeting of the World Society for Pediatric Infectious Diseases. Buenos Aires: WSPID; 2009 [http://www.abstractserver.com/wspid09/planner/sp.php?go=abstract&action=abstract_iplanner&absno=455]

96. Gligo ND, Cane AD, Micone P, Gentile A: Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine 2010, 28:2020–2030.

97. Grupo de Trabajo de SIREVA II: Informe Regional de SIREVA II: Organización Panamericana de la Salud. Informe Regional de SIREVA II, 2009: datos por país y por grupo de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasivos. (Series Documentos técnicos. Tecnologías esenciales de salud. THS/EV-2009/002). Washington: OPS; 2009.

98. Brandileone MC, Vieira VS, Casagrande ST, Zanella RC, Guerra ML, Bokkerm S, De Moraes JC, Balacci BR, Charmone CB, Oliveira MA, De Matos DG, Arruda TM, Coelho MF, D’Avila SM, Dos Santos AR, Di Fabio JL: Prevalence of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated from Brazilian children with invasive infections. Pneumococcal Study Group in Brazil for the SIREVA Project. Regional System for Vaccines in Latin America. Microb Drug Res 2009, 3:141–145.

99. Castañeda E, Leal AL, Castillo G, De La Hoz F, Vela MC, Arango M, Trujillo H, Levy A, Gema A, Calle M, Valencia ML, Parra W, Aguileo N, Mejia Gl, Jaramillo S, Montoya F, Porras H, Sanchez A, Saa D, Di Fabio JL, Homma A: Distribution of capsular types and antimicrobial susceptibility of invasive isolates of Streptococcus pneumoniae in Colombian children. Microb Drug Res 1997, 3:147–152.

100. Echáñez-Aviles G, Velázquez-Meza ME, Carranza-Barajas MN, Soto-Noguerón A, Solórzano-Santos F, Pérez Miravete A, Gatica-Marquina R, di Fabio JL: Antimicrobial susceptibilities and capsular types of invasive Streptococcus pneumoniae isolated in children in Mexico City. Microb Drug Res 1997, 3:153–157.

101. Botello M, Algora G, Bianchi H, Horta-Trejo G, Cesaria I, Camacho T, Castro M, De Los Santos M, Delez R, Dell’Acaia L, Gallana A, Giordano A, Giordano P, Lopez-Gomez GM, Milaneses MG, Molina R, Pedreira W, Pirano A, Pixel L: Capsular type distribution and susceptibility to antibiotics of Streptococcus pneumoniae clinical strains isolated from Uruguayan children with systemic infections. Microb Drug Res 1997, 3:159–164.

102. Rossi A, Ruvinsky R, Regueira M, Corso A, Pace J, Gentile A, Di Fabio JL: Distribution of capsular types and penicillin-resistance of strains of Streptococcus pneumoniae causing systemic infections in Argentinean children under 5 years of age. Streptococcus pneumoniae Working Group. Microb Drug Res 1997, 3:135–140.

103. Kertesz DA, Di Fabio JL, de Cunto Brandileone MC, Castañeda E, Echáñez-Aviles G, Heitmann I, Homma A, Hortal M, Lovgren M, Ruvinsky RD, Talbot JA, Weekes J, Spika JS: Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization Surveillance Study. Clin Infect Dis 1998, 26:1355–1361.

104. Tomasz A, Corso A, Severina EP, Echáñez-Aviles G, Brandileone MC, Camacho T, Castañeda E, Figueroa O, Rossi A, Di Fabio JL: Molecular epidemiologic characterization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin-American countries: an overview. Microb Drug Res 1998, 4:195–207.
105. Levine MM, Lagos R, Levine OS, Heitmann I, Enriquez N, Pinto ME, Alvarez AM, Wu E, Mayorga C, Reyes A: Epidemiology of invasive pneumococcal infections in infants and young children in Metropolitan Santiago, Chile, a newly industrializing country. Pediatr Infect Dis J 1998, 17:287–293.

106. Leal AL, Castañeda E: Susceptibility to antimicrobial agents in isolates of invasive Streptococcus pneumoniae in Colombia. Pan Am J Public Health 1999, 15:157–163.

107. Gomez Barreto D, Calderon-James E, Rodriguez RS, De Los Monteros LEE: Clinical outcome of invasive infections in children caused by highly penicillin-resistant Streptococcus pneumoniae compared with infections caused by penicillin-susceptible strains. Arch Med Res 2000, 31:592–596.

108. Hortal M, Ruvinrsky R, Rossi A, Agudelo CI, Castañeda E, Brandileone MC, Camou T, Palacio R, Echániz G, Di Fabio JL: Impacto de Streptococcus pneumoniae en las neumonías del niño latinoamericano. Grupo SIREVA-Vigia I. Rev Panam Salud Pública 2000, 8:185–195.

109. Hortal M, Lovgren M, de la Hoz F, Agudelo CI, Brandileone MC, Camou T, Casagrande S, Castañeda E, Corso A, Echániz G, Hormazabal JC, Pace J, Palacio R, Perez-Goffin R, Ruvinrsky R, Di Fabio JL, the PAHO SIREVA-Vigia Study Groups: Antibiotic resistance in Streptococcus pneumoniae in six Latin American countries: biological and therapeutic implications. Micron 2001, 32:391–401.

110. Nascimento-Carvalho CM, Lopes AA, Gomes MD, Magalhães AP, Pinto AS: Conjugate vaccine formulations. In Uruguayan children: Comparison between serotype distribution and susceptibility and serotypes of nasopharyngeal nasopharyngeal Streptococcus pneumoniae in children with pneumonia and in children attending day-care centres in Fortaleza, Brazil. Int J Antimicrob Agents 2002, 20:860–862.

111. Ruvinrsky R, Gentile A, Regueira M, Corso A: Infecciones invasivas por Streptococcus pneumoniae: estudio epidemiológico e importancia del desarrollo de un sistema de vigilancia. Arch Argent Pediatr 2002, 100:31–43.

112. Camou T, Palacio R, Di Fabio JL, Hortal M: Invasive pneumococcal diseases in Urban children: Comparison between serotype distribution and conjugate vaccine formulations. Vaccine 2003, 21:2102–2105.

113. Grupo Multifuncional de Neumonías: Vigilancia epidemiológica del cisténtil de Haemophilus influenzae y Streptococcus pneumoniae en menores de 5 años en el Perú. Rev Peru Med Exp Salud Pública 2003, 20:150–155.

114. Magálahe AP, Pinto AS: Antimicrobial resistance and serotyping Streptococcus pneumoniae isolated from pediatric patients in Belo Horizonte, MG, Brazil. Braz J Microbiol 2003, 34:210–212.

115. Moreno J, Phanthavanouvong V, Castañeda E: Vigilancia molecular de aislamientos invasores de Streptococcus pneumoniae resistentes a la penicilina en niños colombianos menores de 5 años. Biomédica 2004, 24:296–301.

116. Ochoa TJ, Rupa R, Guerra H, Hernandez H, Chaparro E, Wanger A, Mason EO Jr: Penicillin resistance and serotypes/ serogroups of S. pneumoniae in nasopharyngeal carrier children younger than 2 years in Lima, Peru. Diagn Microbiol Infect Dis 2005, 52:59–64.

117. Zemlicková H, Crisóstomo MI, Brandileone MC, Camou T, Castañeda E, Corso A, Echániz-Aviles G, Páez M, Tomasz A: Serotypes and clonal types of penicillin-susceptible Streptococcus pneumoniae causing invasive disease in children in five Latin American countries. Microb Drug Resist 2005, 11:195–204.

118. Agudelo CI, Moreno J, Sanabria OM, Ovalle MV, Di Fabio JL, Castañeda E: Streptococcus pneumoniae: Evolución de los serotipos y los patrones de resistencia antimicrobiana en aislamientos invasores en 11 años de vigilancia en Colombia (1994 – 2004). Grupo colombiano de trabajo en S. pneumoniae. Biomédica 2006, 26:234–249.

119. Bricks LF, Berezin E: Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases. J Pediatr (Rio J) 2006, 82(3 Suppl):S67–S74.

120. Lagos RM, Muñoz AE, Levine MM: Prevalence of pneumococcal bacteraemia among children <36 months of age presenting with moderate fever to pediatric emergency rooms of the Metropolitan Region (Santiago), Chile. Human Vaccines 2006, 2:129–133.

121. Tigue V, Alvis N, Parodi R, Bustos A, Mattar S: Meningitis agudas en Córdoba, 2002–2004. Rev Salud Pública (Bogota) 2006, 8(Suppl 1):33–46.

122. Tregnaghi M, Ceballos A, Rüttimann R, Ussher J, Tregnaghi P, Peerers P, Hausdorff WP: Active epidemiologic surveillance of pneumonia and invasive pneumococcal disease in ambulatory and hospitalized infants in Córdoba, Argentina. Pediatr Infect Dis J 2006, 25:370–372.

123. Ferrari Castilla AM, Pérez GMC, Martínez AA, Algora RG, Chamorro VF, Gualía BWI, Zabala Ch C, Giachetto LG, Montano LA: Etiología de la neumonía bacteriana adquirida en la comunidad en niños hospitalizados. Uruguay 1998-2004. Rev Chilena Infectol 2007, 24:40–47.

124. Lovgren M, Talbot JA, Brandileone MC, Casagrande ST, Agudelo CI, Castañeda E, Regueira M, Corso A, Heitmann L, Maldonado A, Echániz-Aviles G, Soto-Noquerón A, Hortal M, Camou T, Gabastou JM, Di Fabio JL, SIREVA Study Group: Evolution of an international external quality assurance model to support investigation of Streptococcus pneumoniae, developed for the SIREVA Project in Latin America, from 1993 to 2005. J Clin Microbiol 2007, 45:3184–3190.

125. Vieira A, Gomes C, Polo M, Eudes J, Bello EJM, Figueiredo R: Streptococcus pneumoniae: estudio de cepas isoliadas de liquor. J Pediatr (Rio J) 2007, 83:71–78.

126. Abarca VK, Vergara FR, Tassara PE, Ibáñez WL, García BC, Potin SM: Invasive pneumococcal disease and consolidated pneumonia in infants: one year of surveillance in three Chilean health care centers. Rev Chilena Infectol 2008, 23:59–103. SIREVA.

127. Gabastou JM, Agudelo CI, Brandileone MC, Castañeda E, de Leons AP, Di Fabio JL: Caracterización de aislamientos invasivos de S. pneumoniae, H influenzae y N. meningitidis en América Latina y el Caribe: SIREVA II, 2000–2005. Rev Panam Salud Pública 2008, 24:1–15.

128. Hortal M, Sebaiague G, Camou T, Iraola J, Estevan M, Pujadas M: Pneumococcal pneumonia in hospitalized Uruguayan children and potential prevention with different vaccine formulations. J Pediatr 2008, 152:850–853.

129. Mayoral C, Baroni MR, Giani R, Virgolini S, Zurbiggren L, Regueira M: Distribución de serotipos de Streptococcus pneumoniae aislados de infecciones invasoras en el Hospital de Niños de Santa Fe. Rev Argent Microbiol 2008, 40:13–16.

130. Pérez García MC, Giachetto Larraz G, Romero Rostagno C, Zabala Chain C, Algora Ruishol G, Montano Loito A, Ferrari Castilla Aht: Neumonía neumocócica invasiva en niños de 0 a 24 meses: ¿influye la resistencia bacteriana en la evolución? An Pediatr (Barc) 2008, 69:205–209.

131. Agudelo CI, Castañeda E, Corso A, Regueira M, Brandileone MC, Brändrup AO, Maldonado A, Hormazabal JC, Tamargo I, Echániz-Aviles G, Soto A, Viveros MG, Hernández J, Chamorro G, Weiler N, Sánchez J, Fersis JM, Camou T, García G, Espadola E, Payares D, Gabastou JM, Di Fabio JL, Grupo Sireva II: Resistencia a antibióticos no betalactámicos de aislamientos invasores de Streptococcus pneumoniae en niños latinosamericanos. SIREVA II, 2000–2005. Rev Panam Salud Pública 2009, 22:305–313.

132. Mantese OC: Prevalence of serotypes and antimicrobial resistance of invasive strains of pneumococcal in children: analysis of 9 years. J Pediatr (Rio J) 2009, 85:495–502.

133. Lagos R, Muñoz A, Valenzuela MT, Heitmann I, Levine MM: Population-based surveillance for hospitalized and ambulatory pediatric invasive pneumococcal disease in Santiago, Chile. Pediatr Infect Dis J 2002, 21:115–1123.

134. Gudowicz L, Perez AE: Bacterial meningitis in children and adolescents: an observational study based on the national surveillance system. BMC Infect Dis 2005, 5:103. doi:10.1186/1471-2334-12-124

Cite this article as: Castañeda et al.: Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990–2010. BMC Infectious Diseases 2012 12:124.